Senior Research Associate
Norwich, UNITED KINGDOM
His research is in the diagnosis of, and the prediction of treatments for, prostate cancer.
The Star Online online
Lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School, said: “Prostate cancer is the most common cancer in men in Britain. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men.view more
Medical News Today online
As lead researcher Dr. Jeremy Clark explains, “Because the prostate is constantly secreting, the collection of urine from men’s first urination of the day means that the biomarker levels from the prostate are much higher and more consistent.”view more
International Business Times online
As per the researchers, led by Dr. Jeremy Clark, "The PUR test looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or 'low risk.”view more
“Being able to simply provide a urine sample at home and post a sample off for analysis could really revolutionise diagnosis,” said lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School.view more
Sky News online
Lead researcher Dr Jeremy Clark, from UEA's Norwich Medical School, said: "The PUR test looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or 'low risk'.view more
Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically implementable tools able to precisely and noninvasively identify patients that can either be safely removed from treatment pathways or those requiring further follow up.
Unsupervised learning methods, such as Hierarchical Cluster Analysis, are commonly used for the analysis of genomic platform data. Unfortunately, such approaches ignore the well-documented heterogeneous composition of prostate cancer samples. Our aim is to use more sophisticated analytical approaches to deconvolute the structure of prostate cancer transcriptome data, providing novel clinically actionable information for this disease.
To develop a risk classifier using urine‐derived extracellular vesicle (EV)‐RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS).
Liquid biopsies that noninvasively detect molecular correlates of aggressive prostate cancer (PCa) could be used to triage patients, reducing the burdens of unnecessary invasive prostate biopsy and enabling early detection of high-risk disease.
Urine from patients with prostate cancer (PCa) contains gene transcripts that have been used for PCa diagnosis and prognosis. Historically, patient urine samples have been collected after a digital rectal examination of the prostate, which was thought necessary to boost the levels of prostatic secretions in the urine.